Fig. 3: Subgroup analysis of major pathological response in per-protocol population (CA-SAP [n = 49] vs. SAP [n = 50]). | Nature Communications

Fig. 3: Subgroup analysis of major pathological response in per-protocol population (CA-SAP [n = 49] vs. SAP [n = 50]).

From: Neoadjuvant camrelizumab and apatinib combined with chemotherapy versus chemotherapy alone for locally advanced gastric cancer: a multicenter randomized phase 2 trial

Fig. 3

Forest plots show the risk ratios (RRs) as centers, the upper and lower hinges represent the corresponding 95% confidence intervals (CIs). Interaction between agents was evaluated by likelihood ratio test, and P values were two sided at the 5% significance level. No adjustments were made for multiple comparisons. CA-SAP camrelizumab, apatinib, nab-paclitaxel, and S-1, SAP nab-paclitaxel and S-1, ECOG Eastern Cooperative Oncology Group, PD-L1 programmed death-ligand 1, CPS combined positive score, MSI microsatellite instability, MSS microsatellite stable. Source data are provided as a Source Data file.

Back to article page